Catalent, Inc. (CTLT)
| Market Cap | 10.67B |
| Revenue (ttm) | 4.42B |
| Net Income (ttm) | -413.00M |
| Shares Out | 181.51M |
| EPS (ttm) | -2.28 |
| PE Ratio | n/a |
| Forward PE | 52.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,724,277 |
| Open | 59.10 |
| Previous Close | 59.10 |
| Day's Range | 58.58 - 59.13 |
| 52-Week Range | 36.74 - 61.20 |
| Beta | 1.16 |
| Analysts | Hold |
| Price Target | 59.83 (+1.79%) |
| Earnings Date | Nov 5, 2024 |
About CTLT
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syring... [Read more]
Financial Performance
In 2024, Catalent's revenue was $4.38 billion, an increase of 2.77% compared to the previous year's $4.26 billion. Losses were -$1.04 billion, 307.4% more than in 2023.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CTLT stock is "Hold." The 12-month stock price forecast is $59.83, which is an increase of 1.79% from the latest price.
News
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matt...
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
Catalent, Inc. Reports First Quarter Fiscal 2025 Results
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the f...
EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6
EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer Catalent , according to a filing on the European Commission website on Monday.
Roche comes out against clearing takeover of drug manufacturer Catalent
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers.
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug ma...
Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to c...
Consumer groups ask FTC to block Novo Holdings-Catalent deal
Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's controlling shareholder from acquiring contract drug manufacturer Catal...
Catalent to sell New Jersey facility
Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday.
Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent
Ghent, Belgium, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands ...
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a ...
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalen...
Catalent delays filing of annual report
Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent
Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the f...
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansion ...
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
Catalent stockholders approve deal with Novo Holdings
Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo Nordisk.
Catalent Stockholders Approve Transaction with Novo Holdings
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Spec...
Surely Wines Appoints Brandon Joldersma as New CEO
AUSTIN, Texas--(BUSINESS WIRE)--Surely Wines, a trailblazer in the premium non-alcoholic wine space, is pleased to announce the appointment of Brandon Joldersma as the company's new Chief Executive Of...
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT) (“Catalent”), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial resu...
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of b...
FTC Seeks More Information on $16.5 Billion Novo-Catalent Deal
The request signals that the agency is reviewing whether the deal could be anticompetitive under U.S. law.
US FTC seeks more information on Novo Nordisk parent-Catalent deal
The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's parent to buy manufacturing subcontractor Catalent.
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
SAN DIEGO--(BUSINESS WIRE)---- $CTLT #CTLT--Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT).